Compare ONL & TTRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ONL | TTRX |
|---|---|---|
| Founded | 2021 | 2015 |
| Country | United States | United States |
| Employees | N/A | 2 |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 165.4M | 281.2M |
| IPO Year | 2021 | N/A |
| Metric | ONL | TTRX |
|---|---|---|
| Price | $2.64 | $8.07 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $3.00 | ★ $8.00 |
| AVG Volume (30 Days) | ★ 199.7K | 125.6K |
| Earning Date | 05-07-2026 | 05-31-2026 |
| Dividend Yield | ★ 2.83% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $147,647,000.00 | N/A |
| Revenue This Year | $4.10 | N/A |
| Revenue Next Year | $3.10 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.92 | $2.57 |
| 52 Week High | $3.04 | $11.69 |
| Indicator | ONL | TTRX |
|---|---|---|
| Relative Strength Index (RSI) | 41.84 | 47.75 |
| Support Level | $2.62 | $4.40 |
| Resistance Level | $2.71 | $11.69 |
| Average True Range (ATR) | 0.07 | 1.04 |
| MACD | -0.01 | -0.22 |
| Stochastic Oscillator | 28.85 | 4.52 |
Orion Properties Inc is an internally managed real estate investment trust engaged in the ownership, acquisition, and management of a diversified portfolio of office properties located in high-quality suburban markets across the United States and leased mainly on a single-tenant net lease basis to creditworthy tenants. Its portfolio is comprised of traditional office properties, as well as governmental, medical office, flex/laboratory, and R&D and flex/industrial properties. The company is focused on shifting its portfolio concentration over time away from traditional office properties, towards more dedicated use assets with specialized uses that include an office component. It operates in one business segment: commercial real estate.
Turn Therapeutics Inc is a clinical-stage biotechnology and medical device development company built around its proprietary platform technology called PermaFusion designed to enhance drug performance. The company is developing non-systemic, non-biologic topical immunomodulators for inflammatory skin disease. Its program, GX-03, is being studied for moderate-to-severe eczema based on preclinical evidence of cytokine inhibition and reduced eczema severity, as well as a favorable real-world tolerability record from prior cleared medical device indications for the same formula. GX-03 is currently being evaluated in an ongoing, randomized, double-blind, vehicle-controlled clinical study designed to assess its potential as a topical treatment for moderate-to-severe eczema.